Company intelligence / Profile preview
Surface Ophthalmics
Pleasanton, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Surface Ophthalmics has advanced three proprietary investigational therapies (SURF-100, SURF-200, and SURF-201) into and through Phase II trials for dry eye syndrome and post-surgical ocular pain; over 550 patients have been evaluated in well-controlled U.S. studies, and the company is preparing for further studies and eventual commercialization[2][5].
- Therapeutic areas
- Ophthalmology
- Modalities
- Small moleculeBiologicTopical ophthalmic solutionOral capsule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Imprimis Pharmaceuticals
Beyond the preview
Go deeper on Surface Ophthalmics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Surface Ophthalmics.